In recommending Kimmtrak, NICE factored in a new commercial agreement with the sponsor and changed its 2023 negative opinion.

Novartis licensed PTC's PTC518 Huntington's disease program and related molecules and will pay $1 billion upfront as well as other costs.

In the study, the firm will enroll previously treated patients whose tumors are positive for FRα based on IHC testing.

A neurologist orders the wrong genetic test for a patient experiencing peripheral neuropathy and doesn't realize it even upon ...

The trials are evaluating an individualized neoantigen vaccine with Keytruda as an adjuvant therapy for non-small cell lung cancer.

The firm plans to put the proceeds toward further developing its cell therapy in CD33- or FLT3-expressing AML and for other R&D activities.

The agency is also evaluating if there's a need for further regulatory action based on reports of hematologic malignancies from clinical trials of the therapy.

The global Phase III VANCE trial of the autologous EBV-targeted T-cell therapy was the largest trial of a solid tumor cell ...

The Missouri hospital system designed its own 13-gene PGx panel, which it runs at its molecular genetics lab and calls the ...

The EC considered the treatment's activity in patients with advanced, PD-L1-positive esophageal and gastric cancers in the RATIONALE-305 and -306 trials.

Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.

The Swedish firm plans to expand the VIDAR-1 umbrella trial to study additional KRAS-targeting product candidates in the future.